{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:34:16Z","timestamp":1760132056296,"version":"3.37.3"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Ixabepilone is a novel microtubule-stabilizing agent with clinical efficacy in advanced breast cancer, including patients whose disease has progressed on prior anthracyclines and taxanes. The safety profile of single-agent ixabepilone and combination ixabepilone plus capecitabine therapy is reviewed, outlining the steps to effectively manage and prevent common adverse events. Ixabepilone is generally well tolerated, and importantly, its toxicity profile does not overlap with that of capecitabine. Peripheral sensory neuropathy and neutropenia are the most common toxicities associated with ixabepilone; both can be effectively managed by monitoring patients and then, depending on severity, instituting a treatment delay until recovery and reducing the ixabepilone dose for subsequent treatment cycles. Ixabepilone dose reductions are recommended for most grade 3 events, excluding transient fatigue, arthralgia, and myalgia, whereas treatment discontinuation is recommended for persistent grade 3 neuropathy or any grade 4 nonhematological toxicity. Because ixabepilone exposure is greater in patients with hepatic impairment and those receiving concomitant strong cytochrome P-450 CYP3A4 inhibitors, dose adjustments and restrictions are recommended according to the degree of hepatic impairment, whether ixabepilone is administered alone or in combination with capecitabine, and whether a strong CYP3A4 inhibitor is being coadministered. Patients should be premedicated with oral H1 and H2 antihistamines to prevent hypersensitivity reactions. Unlike taxanes, corticosteroid premedication is not required unless a hypersensitivity reaction occurred during a previous cycle or during treatment with another Cremophor-containing agent. By effectively managing adverse events and taking steps to minimize them, clinicians can ensure that patients derive the maximum benefit from ixabepilone therapy.<\/jats:p>","DOI":"10.1634\/theoncologist.2008-0284","type":"journal-article","created":{"date-parts":[[2009,5,2]],"date-time":"2009-05-02T00:24:28Z","timestamp":1241223868000},"page":"448-455","source":"Crossref","is-referenced-by-count":15,"title":["Proactive Management of Adverse Events Maintains the Clinical Benefit of Ixabepilone"],"prefix":"10.1093","volume":"14","author":[{"given":"Denise A.","family":"Yardley","sequence":"first","affiliation":[{"name":"a Sarah Cannon Research Institute, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,5,1]]},"reference":[{"key":"2021122207503586300_R1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1634\/theoncologist.2007-0167","article-title":"Ixabepilone: A novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms","volume":"13","author":"Vahdat","year":"2008","journal-title":"The Oncologist"},{"key":"2021122207503586300_R2","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1200\/JCO.2004.12.001","article-title":"Epothilones: Mechanism of action and biologic activity","volume":"22","author":"Goodin","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122207503586300_R3","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1021\/bi0121611","article-title":"Epothilone and paclitaxel: Unexpected differences in promoting the assembly and stabilization of yeast microtubules","volume":"41","author":"Bode","year":"2002","journal-title":"Biochemistry"},{"key":"2021122207503586300_R4","first-page":"1429","article-title":"BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy","volume":"7","author":"Lee","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2021122207503586300_R5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00280-008-0727-5","article-title":"Preclinical efficacy spectrum and pharmacokinetics of ixabepilone","volume":"63","author":"Lee","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"issue":"suppl 7","key":"2021122207503586300_R6","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1053\/j.seminoncol.2005.09.013","article-title":"Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR)","volume":"32","author":"Lee","year":"2005","journal-title":"Semin Oncol"},{"key":"2021122207503586300_R7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-0-387-74039-3_2","article-title":"Roles of multidrug resistance genes in breast cancer chemoresistance","volume":"608","author":"Kuo","year":"2007","journal-title":"Adv Exp Med Biol"},{"key":"2021122207503586300_R8","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1200\/JCO.2006.09.3849","article-title":"Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine","volume":"25","author":"Perez","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122207503586300_R9","first-page":"5210","article-title":"Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment","volume":"25","author":"Thomas","year":"2007","journal-title":"J Clin Oncol 2007;"},{"key":"2021122207503586300_R10","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1200\/JCO.2006.08.9102","article-title":"Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer","volume":"25","author":"Thomas","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122207503586300_R11","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1200\/JCO.2005.10.024","article-title":"Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer","volume":"23","author":"Low","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207503586300_R12","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1200\/JCO.2006.09.7535","article-title":"Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy","volume":"25","author":"Roch\u00e9","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122207503586300_R13","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.2006.10.0784","article-title":"Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes","volume":"25","author":"Denduluri","year":"2007","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2021122207503586300_R14","first-page":"S31","article-title":"Predicting response to ixabepilone: Genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer (BC)","volume":"94","author":"Baselga","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"2021122207503586300_R15","doi-asserted-by":"crossref","first-page":"597s","DOI":"10.1200\/jco.2006.24.18_suppl.12017","article-title":"Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"journal-title":"ASCO 2008 Breast Cancer Symposium Proceedings, Abstract 186","article-title":"Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: Results from two randomized phase III trials","author":"Hortobagyi","key":"2021122207503586300_R16"},{"volume-title":"Ixempra\u2122 Kit (ixabepilone) for injection [package insert]","year":"2007","key":"2021122207503586300_R17"},{"issue":"18 suppl","key":"2021122207503586300_R18","first-page":"88s","article-title":"Final results from a phase I trial of ixabepilone given every three weeks in patients with advanced malignancies and lymphoma","volume":"24","author":"Aghajanian","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122207503586300_R19","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122207503586300_R20","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1200\/JCO.2005.04.0543","article-title":"Peripheral neuropathy induced by microtubule-stabilizing agents","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122207503586300_R21","first-page":"294","article-title":"Peripheral neuropathy: Pathogenic mechanisms and alternative therapies","volume":"11","author":"Head","year":"2006","journal-title":"Altern Med Rev"},{"issue":"suppl 1","key":"2021122207503586300_R22","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/annonc\/mdl449","article-title":"Supportive care","volume":"18","author":"Ludwig","year":"2007","journal-title":"Ann Oncol"},{"key":"2021122207503586300_R23","first-page":"1207","article-title":"Primary care of the patient with cancer","volume":"75","author":"Smith","year":"2007","journal-title":"Am Fam Physician"},{"issue":"suppl 1","key":"2021122207503586300_R24","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ejon.2004.06.007","article-title":"Management of hand-foot syndrome in patients treated with capecitabine (Xeloda)","volume":"8","author":"Lassere","year":"2004","journal-title":"Eur J Oncol Nurs"},{"key":"2021122207503586300_R25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1078155206069242","article-title":"Management of hand-foot syndrome induced by capecitabine","volume":"12","author":"Gressett","year":"2006","journal-title":"J Oncol Pharm Pract"},{"key":"2021122207503586300_R26","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1158\/1078-0432.CCR-07-4151","article-title":"The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: A first in class epothilone B analogue in late-phase clinical development","volume":"14","author":"Goel","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122207503586300_R27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/00003088-200342020-00002","article-title":"Clinical pharmacokinetic profile of modafinil","volume":"42","author":"Robertson","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"2021122207503586300_R28","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2165\/00003495-200363150-00003","article-title":"Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management","volume":"63","author":"Verstappen","year":"2003","journal-title":"Drugs"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2008-0284","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2008-0284","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/5\/448\/41841277\/oncolo_14_5_448.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/5\/448\/41841277\/oncolo_14_5_448.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T09:39:13Z","timestamp":1640165953000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/14\/5\/448\/6397859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,1]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2009,5,1]]},"published-print":{"date-parts":[[2009,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2008-0284","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2009,5,1]]},"published":{"date-parts":[[2009,5,1]]}}}